Heparin-binding protein levels predict unfavorable outcome in COVID-19 pneumonia: A post-hoc analysis of the SAVE trial
Description
We aimed to evaluate heparin-binding protein (HBP) as a marker of prognosis of unfavorable outcome in COVID-19 pneumonia. This was a post-hoc analysis of the SAVE clinical trial investigating anakinra treatment, guided by suPAR (soluble urokinase
